Showing results (141-150 of 163) with videos related to

Sort By:
Pageof 17
Cancer Medicine|June 6, 2022
Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinibAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology|June 12, 2023
Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve FunctionAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.
Oncology|August 8, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical SettingsHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancer Medicine|November 21, 2023
Comparing the impact of atezolizumab plus bevacizumab and lenvatinib on the liver function in hepatocellular carcinoma patients: A mixed-effects regression model approachTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Scientific Reports|January 3, 2025
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinibHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Clinical and Molecular Hepatology|July 11, 2024
Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)Chuan Liu, Hong You, Qing-Lei Zeng, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2023
Comparative analysis of the therapeutic outcomes of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma patients aged 80 years and older: Multicenter studyTakeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|October 4, 2023
Comparison of prognostic impact of atezolizumab plus bevacizumab versus lenvatinib in patients with intermediate-stage hepatocellular carcinomaToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.
Cancer Reports (Hoboken, N.J.)|April 5, 2024
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinomaHideko Ohama, Atsushi Hiraoka, Toshifumi Tada, et al.
Cancers|September 9, 2023
Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective StudyKazunari Tanaka, Kunihiko Tsuji, Atsushi Hiraoka, et al.
Pageof 17